Success stories

Rupture of common iliac or aortoiliac aneurysm is fatal in more than eight out of 10 cases. Main objectives were to describe inhospital management and estimate morbidity/mortality in patients implanted with an iliac branched endoprosthesis (IBE)

The GORE-EPI study, conducted by RCTs using the French healthcare database system (Système National des Données de Santé (SNDS)), evaluated the real-life long-term morbidity and mortality of patients implanted with the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE). The main outcome was a composite endpoint including events such as mortality, aortic endovascular reintervention (AER), embolizations for endoleak, branch thrombectomy, or bypass surgeries. The results showed that at one and two years after implantation, respectively 84% and 79% of patients were free from any morbidity or mortality event.

This study demonstrates the value of SNDS in long-term evaluation using clinical endpoints of almost all patients implanted in France with the studied medical device, with no patients lost to follow-up.

N° T28825232020111 (https://www.health-data-hub.fr/projets/etude-post-inscription-de-gorer-excluderr-iliac-branch-endoprosthesis-ibe-lanalyse-des)

Data Controller: W.L. GORE

Data Processor: RCTs

Scientific Committee: Antoine Million, Elixène Jean-Baptiste, Fanny Raguideau
IBE

https://www.valueinhealthjournal.com/article/S1098-3015(23)05377-9/abstract

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

TFR
Success stories

Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

TKI
Success stories

Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life” Settings: A Population-Based Study Using a Nationwide Claim Database

nv1
Success stories

Evaluation clinique des DMs implantables de Novastep selon le Règlement Européen 2017/745